JP2023517611A5 - - Google Patents

Info

Publication number
JP2023517611A5
JP2023517611A5 JP2022554632A JP2022554632A JP2023517611A5 JP 2023517611 A5 JP2023517611 A5 JP 2023517611A5 JP 2022554632 A JP2022554632 A JP 2022554632A JP 2022554632 A JP2022554632 A JP 2022554632A JP 2023517611 A5 JP2023517611 A5 JP 2023517611A5
Authority
JP
Japan
Prior art keywords
approximately
composition
antibody
use according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/056113 external-priority patent/WO2021180821A2/en
Publication of JP2023517611A publication Critical patent/JP2023517611A/ja
Publication of JP2023517611A5 publication Critical patent/JP2023517611A5/ja
Pending legal-status Critical Current

Links

JP2022554632A 2020-03-10 2021-03-10 Il-6/il-6r抗体の組成物及びその使用方法 Pending JP2023517611A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062987837P 2020-03-10 2020-03-10
US62/987,837 2020-03-10
US202063006612P 2020-04-07 2020-04-07
US63/006,612 2020-04-07
US202063014800P 2020-04-24 2020-04-24
US63/014,800 2020-04-24
PCT/EP2021/056113 WO2021180821A2 (en) 2020-03-10 2021-03-10 Compositions of il-6/il-6r antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023517611A JP2023517611A (ja) 2023-04-26
JP2023517611A5 true JP2023517611A5 (cg-RX-API-DMAC7.html) 2024-03-19

Family

ID=74871406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554632A Pending JP2023517611A (ja) 2020-03-10 2021-03-10 Il-6/il-6r抗体の組成物及びその使用方法

Country Status (8)

Country Link
US (2) US20210284743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4117727A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023517611A (cg-RX-API-DMAC7.html)
CN (1) CN115697403A (cg-RX-API-DMAC7.html)
AU (1) AU2021234094A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169827A1 (cg-RX-API-DMAC7.html)
IL (1) IL296276A (cg-RX-API-DMAC7.html)
WO (1) WO2021180821A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121455A1 (en) * 2020-03-18 2023-01-25 Vitaeris Inc. Use of anti-il-6 antibody, e.g., clazakizumab for treatment/prevention of ards associated with coronavirus (covid-19) infection
WO2022006051A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating covid-19 by inhalation
US20230227555A1 (en) * 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
US12552861B2 (en) * 2021-10-08 2026-02-17 National Taiwan University Monoclonal antibody
WO2025122924A1 (en) * 2023-12-07 2025-06-12 Tourmaline Bio, Inc. Methods for the prevention and treatment of long covid and related symptoms

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
JP2011520898A (ja) * 2008-05-13 2011-07-21 ノビミューン エスアー 抗il−6/il−6r抗体およびそれらの使用方法
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il­6의 길항제
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
BR112019006853B1 (pt) * 2016-10-31 2021-08-24 Fresenius Kabi Deutschland Gmbh Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use

Similar Documents

Publication Publication Date Title
KR102390714B1 (ko) 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
US20230201497A1 (en) Method for pulsatile delivery of a gaseous drug
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
JP2023521623A (ja) 過炎症性症候群の処置
JP2023517611A (ja) Il-6/il-6r抗体の組成物及びその使用方法
JP2022531205A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
CN116406274B (zh) 用于治疗冠状病毒的cd3抗体
JP2023533658A5 (cg-RX-API-DMAC7.html)
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
JP2022553703A5 (cg-RX-API-DMAC7.html)
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2024535009A5 (cg-RX-API-DMAC7.html)
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
CN118922432A (zh) 用于治疗细胞因子风暴的组合物和方法
HK40086385A (en) Method for pulsatile delivery of a gaseous drug
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2023521667A5 (cg-RX-API-DMAC7.html)
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab